Form 4: Align Technology Director Equity Transaction

Director Andrea Lynn Saia acquired 1,745 shares of Align Technology common stock through the vesting of restricted stock units.

Summary

• Director Andrea Lynn Saia acquired 1,745 shares of Align Technology (ALGN) common stock on May 20, 2026, following the vesting of restricted stock units (RSUs).
• The reporting person was granted 1,836 new RSUs on May 20, 2026, which are scheduled to vest on May 20, 2027, or the date of the next annual meeting of stockholders.
• Following these transactions, the director holds a total of 17,318 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director equity compensation.

Positives

• The transaction reflects standard equity compensation alignment between the director and the company's long-term performance.

Negatives

• None identified.

Risks

• Future vesting of the 1,836 newly granted RSUs is contingent upon the continued service of the director.

Future Outlook

The director has been granted 1,836 RSUs that are expected to vest on May 20, 2027, subject to continued service.

Industry Context

StockSavvy.ai notes that this filing represents routine equity-based compensation for corporate directors, which is standard practice among large-cap medical device companies to ensure alignment with shareholder interests.

Comparison to Industry Standards

• The equity grant structure is consistent with standard corporate governance practices for S&P 500 companies.
• The vesting schedule aligns with typical annual director compensation cycles seen in the healthcare technology sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• Vesting of 1,836 RSUs on May 20, 2027.

Key Dates

Keywords

Align Technology, ALGN, Form 4, Insider Trading, Equity Compensation, Director Ownership